Model-based meta-analysis of individual patient data for the characterization of intravenous 5-fluorouracil population pharmacokinetics.

Date publication

juin 2026

Journal

Cancer chemotherapy and pharmacology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr SCHMITT Antonin

Tous les auteurs :
Briki M, Thoueille P, Joerger M, Chatelut E, Sterle M, Schmitt A, Wagner AD, Buclin T, Carrara S, Guidi M

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42283826

Résumé

The pharmacokinetics (PK) of 5-fluorouracil (5-FU) has been thoroughly studied over the past decades. Using an individual patient data model-based meta-analysis (IPD-MBMA) approach, this study aims to build a generalized model by combining IPD from multiple studies, investigating the role of lean body mass (LBM) in 5-FU PK, and exploring a model informed precision dosing (MIPD)-based approach for refining its therapeutic drug monitoring (TDM).

Mots clés

Fluorouracil, Model-informed precision dosing, Oncology, Personalised care, Pharmacokinetics, Therapeutic drug monitoring

Référence

Cancer Chemother Pharmacol. 2026 06 12;96(1):